ONGENTYS

Peak

opicapone

NDAORALCAPSULE
Approved
Apr 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
15

Mechanism of Action

Catechol O-Methyltransferase Inhibitors

Pharmacologic Class:

Catechol-O-Methyltransferase Inhibitor

Clinical Trials (5)

NCT04990284Phase 4Completed

eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.

Started Nov 2021
NCT04986995Phase 4Completed

OpicApone Sleep dISorder

Started Jun 2021
NCT04978597Phase 3Completed

Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)

Started May 2021
NCT04986982Phase 4Completed

OpiCapone Effect on Motor Fluctuations and pAiN

Started Feb 2021
NCT03959540N/ACompleted

Safety and Effectiveness of Opicapone Plus Standard of Care in Elderly Patients With Parkinson's Disease

Started Apr 2020

Loss of Exclusivity

LOE Date
Dec 12, 2032
82 months away
Patent Expiry
Dec 12, 2032

Patent Records (5)

Patent #ExpiryTypeUse Code
9550759
Jul 26, 2026
U-3872
8907099
May 12, 2027
Substance
9745290
Oct 10, 2027
Product
U-3869
8168793
Apr 2, 2029
SubstanceProduct
U-3869
8524746
Jul 14, 2029
U-3869